Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report
Autor(a) principal: | |
---|---|
Data de Publicação: | 2020 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Bioscience journal (Online) |
Texto Completo: | https://seer.ufu.br/index.php/biosciencejournal/article/view/48129 |
Resumo: | Many therapies used for cancer (pathology whose cases are progressively increasing in the world) such as chemotherapy and radiotherapy have numerous adverse effects, with cardiotoxicity being one of the most important. This can be defined from the detection, by an imaging method, of a reduction of at least 10% in the left ventricular ejection fraction (LVEF), bringing it to a value below 53%. Anthracyclines (such as Doxorubicin), Trastuzumab, and Taxanes (Docetaxel) are among the most associated chemotherapeutics. To emphasize the importance of optimized treatment for heart failure and to review the main updates on the theme of cardiotoxicity. Case report and bibliographic review on the latest updates to the management of cardiotoxicity and associated heart failure. When correctly identifying the main risk factors associated with chemotherapy and the individual to develop myocardial injury, it is possible to perform the monitoring by means of two main predictors: the myocardial tension strength and the biomarkers. In this sense, changes associated with these predictors may allow early intervention through appropriate treatment and, with the advancement of research, even prevention, mainly using the association of Carvedilol with Enalapril. Continuous monitoring and early initiation of drug therapy for heart failure are clearly associated with a lower degree of myocardial injury and a lower rate of complications. In addition, there is still an increasingly promising possibility in relation to preventive drug therapy, however, there is still a lack of studies on this topic. |
id |
UFU-14_af7212144f6fe24948cd4237a8c5a2a9 |
---|---|
oai_identifier_str |
oai:ojs.www.seer.ufu.br:article/48129 |
network_acronym_str |
UFU-14 |
network_name_str |
Bioscience journal (Online) |
repository_id_str |
|
spelling |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case reportInsuficiência cardíaca grave secundária a cardiotoxicidade com melhora clínica e morfo-funcional após tratamento clínico otimizado: relato de casoCardiac Insufficiency.Early detection.Chemotherapy.Biomarkers.Health SciencesInsuficiência Cardíaca.Detecção precoce.Quimioterápicos.Biomarcadores.Many therapies used for cancer (pathology whose cases are progressively increasing in the world) such as chemotherapy and radiotherapy have numerous adverse effects, with cardiotoxicity being one of the most important. This can be defined from the detection, by an imaging method, of a reduction of at least 10% in the left ventricular ejection fraction (LVEF), bringing it to a value below 53%. Anthracyclines (such as Doxorubicin), Trastuzumab, and Taxanes (Docetaxel) are among the most associated chemotherapeutics. To emphasize the importance of optimized treatment for heart failure and to review the main updates on the theme of cardiotoxicity. Case report and bibliographic review on the latest updates to the management of cardiotoxicity and associated heart failure. When correctly identifying the main risk factors associated with chemotherapy and the individual to develop myocardial injury, it is possible to perform the monitoring by means of two main predictors: the myocardial tension strength and the biomarkers. In this sense, changes associated with these predictors may allow early intervention through appropriate treatment and, with the advancement of research, even prevention, mainly using the association of Carvedilol with Enalapril. Continuous monitoring and early initiation of drug therapy for heart failure are clearly associated with a lower degree of myocardial injury and a lower rate of complications. In addition, there is still an increasingly promising possibility in relation to preventive drug therapy, however, there is still a lack of studies on this topic.Muitas terapias utilizadas para o câncer (patologia cujos casos estão aumentando progressivamente no mundo) como a quimioterapia e a radioterapia possuem inúmeros efeitos adversos, sendo a cardiotoxicidade um dos mais importantes. Esta pode ser definida a partir da detecção, por um método de imagem, de uma redução de, pelo menos, 10% na fração de ejeção do ventrículo esquerdo (FEVE), levando a mesma para um valor inferior a 53%. As Antraciclinas (como a Doxorrubicina), o Trastuzumab, e os Taxanos (Docetaxel) estão entre os quimioterápicos mais associados. Enfatizar a importância do tratamento otimizado para insuficiência cardíaca e revisar sobre as principais atualizações do tema cardiotoxicidade. Relato de caso e revisão bibliográfica sobre últimas atualizações de condutas referentes ao manejo da cardiotoxicidade e insuficiência cardíaca associada. Ao se identificar corretamente os principais fatores de risco associados à quimioterapia e ao indivíduo para desenvolver a injúria miocárdica, é possível realizar o monitoramento por meio de dois preditores principais: a força de tensão miocárdica e os biomarcadores. Nesse sentido, alterações associadas a esses preditores podem permitir a intervenção precoce por meio do tratamento adequado e, com o avanço das pesquisas, até mesmo a realização da prevenção, principalmente utilizando-se a associação de Carvedilol com Enalapril. Monitorização contínua e início precoce da terapia medicamentosa para insuficiência cardíaca estão claramente associadas com um menor grau de injúria miocárdica e um menor índice de complicações. Além disso, ainda há a possibilidade cada vez mais promissora em relação à terapia medicamentosa preventiva, porém, ainda há carência de estudos em relação a este tema.EDUFU2020-12-16info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://seer.ufu.br/index.php/biosciencejournal/article/view/4812910.14393/BJ-v36n6a2020-48129Bioscience Journal ; Vol. 36 No. 6 (2020): Nov./Dec.; 2281-2287Bioscience Journal ; v. 36 n. 6 (2020): Nov./Dec.; 2281-22871981-3163reponame:Bioscience journal (Online)instname:Universidade Federal de Uberlândia (UFU)instacron:UFUenghttps://seer.ufu.br/index.php/biosciencejournal/article/view/48129/30496Brazil; Contemporary Copyright (c) 2020 Pedro Ribeiro Rosa, Igor Mychael Melo Ferreira, Guilherme Silva de Mendonca, Fábio Vieira Fernandes, Rodrigo Penha de Almeida, João Lucas O’Connell, Elmiro Santos Resendehttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessRosa, Pedro RibeiroFerreira, Igor Mychael MeloMendonca, Guilherme Silva deFernandes, Fábio VieiraAlmeida, Rodrigo Penha deO’Connell, João LucasResende, Elmiro Santos 2022-06-10T12:39:44Zoai:ojs.www.seer.ufu.br:article/48129Revistahttps://seer.ufu.br/index.php/biosciencejournalPUBhttps://seer.ufu.br/index.php/biosciencejournal/oaibiosciencej@ufu.br||1981-31631516-3725opendoar:2022-06-10T12:39:44Bioscience journal (Online) - Universidade Federal de Uberlândia (UFU)false |
dc.title.none.fl_str_mv |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report Insuficiência cardíaca grave secundária a cardiotoxicidade com melhora clínica e morfo-funcional após tratamento clínico otimizado: relato de caso |
title |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report |
spellingShingle |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report Rosa, Pedro Ribeiro Cardiac Insufficiency. Early detection. Chemotherapy. Biomarkers. Health Sciences Insuficiência Cardíaca. Detecção precoce. Quimioterápicos. Biomarcadores. |
title_short |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report |
title_full |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report |
title_fullStr |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report |
title_full_unstemmed |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report |
title_sort |
Severe cardiac insufficiency secondary to cardiotoxicity with clinical and morpho-functional improvement after optimised clinical treatment: case report |
author |
Rosa, Pedro Ribeiro |
author_facet |
Rosa, Pedro Ribeiro Ferreira, Igor Mychael Melo Mendonca, Guilherme Silva de Fernandes, Fábio Vieira Almeida, Rodrigo Penha de O’Connell, João Lucas Resende, Elmiro Santos |
author_role |
author |
author2 |
Ferreira, Igor Mychael Melo Mendonca, Guilherme Silva de Fernandes, Fábio Vieira Almeida, Rodrigo Penha de O’Connell, João Lucas Resende, Elmiro Santos |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Rosa, Pedro Ribeiro Ferreira, Igor Mychael Melo Mendonca, Guilherme Silva de Fernandes, Fábio Vieira Almeida, Rodrigo Penha de O’Connell, João Lucas Resende, Elmiro Santos |
dc.subject.por.fl_str_mv |
Cardiac Insufficiency. Early detection. Chemotherapy. Biomarkers. Health Sciences Insuficiência Cardíaca. Detecção precoce. Quimioterápicos. Biomarcadores. |
topic |
Cardiac Insufficiency. Early detection. Chemotherapy. Biomarkers. Health Sciences Insuficiência Cardíaca. Detecção precoce. Quimioterápicos. Biomarcadores. |
description |
Many therapies used for cancer (pathology whose cases are progressively increasing in the world) such as chemotherapy and radiotherapy have numerous adverse effects, with cardiotoxicity being one of the most important. This can be defined from the detection, by an imaging method, of a reduction of at least 10% in the left ventricular ejection fraction (LVEF), bringing it to a value below 53%. Anthracyclines (such as Doxorubicin), Trastuzumab, and Taxanes (Docetaxel) are among the most associated chemotherapeutics. To emphasize the importance of optimized treatment for heart failure and to review the main updates on the theme of cardiotoxicity. Case report and bibliographic review on the latest updates to the management of cardiotoxicity and associated heart failure. When correctly identifying the main risk factors associated with chemotherapy and the individual to develop myocardial injury, it is possible to perform the monitoring by means of two main predictors: the myocardial tension strength and the biomarkers. In this sense, changes associated with these predictors may allow early intervention through appropriate treatment and, with the advancement of research, even prevention, mainly using the association of Carvedilol with Enalapril. Continuous monitoring and early initiation of drug therapy for heart failure are clearly associated with a lower degree of myocardial injury and a lower rate of complications. In addition, there is still an increasingly promising possibility in relation to preventive drug therapy, however, there is still a lack of studies on this topic. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-12-16 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://seer.ufu.br/index.php/biosciencejournal/article/view/48129 10.14393/BJ-v36n6a2020-48129 |
url |
https://seer.ufu.br/index.php/biosciencejournal/article/view/48129 |
identifier_str_mv |
10.14393/BJ-v36n6a2020-48129 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://seer.ufu.br/index.php/biosciencejournal/article/view/48129/30496 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.coverage.none.fl_str_mv |
Brazil; Contemporary |
dc.publisher.none.fl_str_mv |
EDUFU |
publisher.none.fl_str_mv |
EDUFU |
dc.source.none.fl_str_mv |
Bioscience Journal ; Vol. 36 No. 6 (2020): Nov./Dec.; 2281-2287 Bioscience Journal ; v. 36 n. 6 (2020): Nov./Dec.; 2281-2287 1981-3163 reponame:Bioscience journal (Online) instname:Universidade Federal de Uberlândia (UFU) instacron:UFU |
instname_str |
Universidade Federal de Uberlândia (UFU) |
instacron_str |
UFU |
institution |
UFU |
reponame_str |
Bioscience journal (Online) |
collection |
Bioscience journal (Online) |
repository.name.fl_str_mv |
Bioscience journal (Online) - Universidade Federal de Uberlândia (UFU) |
repository.mail.fl_str_mv |
biosciencej@ufu.br|| |
_version_ |
1797069081776488448 |